A – Raju Mohan: Yes, thanks. Yes, this is Raju. So just following up on Bill’s answer to Mike, there’s a lot of focus on this plateauing effect you know last week discussions with the folks. And you know specific to the 15mg and 30mg dose, and these are small trials. There’s a lot of exposure variability amongst these doses, that’s one aspect of it. But the real, I think the real focus should be on the more sensitive endpoints where you clearly see a benefit for higher coverage. You see it for Deucrava, you see it for the NIMBUS Takeda drug and we expect that for our compound as well, right. So I think the totality of this as we should take home, is that from all the trials in psoriasis, all 23 biologics give you about 80% on PASI-75, about 70% on PASI-90 and about 33% to 50% on PASI-100.
That’s the overall efficacy profile we are targeting, right, and we can show that we can achieve biologic-like coverage of IL-23 in our Phase 1 data and we’re targeting biologic-like coverage, biologic-like efficacy in our Phase 2 trials; not only for psoriasis, but for Crohn’s disease and psoriatic arthritis. So really focus on the more sensitive endpoints and cross trial comparisons are difficult. But really as you get to the higher efficacy endpoints like PASI-90 and 100, you will see differentiation with drugs that have higher coverage in IL-23, and that’s what we are targeting. Bill, why don’t you update on the enrollment.
Bill Sandborn : Yes, I mean €“ you know I think we’re circumspect about providing too much details on enrollment, except to say that I’m very comfortable committing to top line data in the fourth quarter of this year, and you know whether it’s early in the fourth quarter or mid or we’ll see, but I’m confident we’ll have data in the fourth quarter.
Yasmeen Rahimi : Thank you so much, and keep up the amazing work.
A – Raju Mohan: Thank you, Yas.
Operator: Thank you. Our next question will come from Matthew Harrison with Morgan Stanley. Your line is open.
Unidentified Analyst: Hi! This is Pete for Matthew. Thanks for taking my question. So I want to ask about the VTX2735, the Phase 2 trial has just started on CAPS. How should we think about the proof of concept, and what should we expect to see in the data? Thank you.
A – Raju Mohan: Yeah, Bill?
Bill Sandborn : Yeah, so as you know, with CAPS they have a variety of symptoms which can include rash, fever, arthritis. There are validated scoring systems that measure those. The patients will not be on a biologic, so they will have stopped a biologic. They’ll be symptomatic and we’re treating them in the context of the trial and expecting to see improvement in the validated symptom measures, which should allow you know relatively direct comparisons to prior Phase 2 and Phase 3 data with the various biologic agents, which include anakinra, rilonacept and canakinumab.
Unidentified Analyst: Got you. Thank you.
Operator: Thank you. Our next question will come from Jeff Jones with Oppenheimer. Your line is open.
Jeff Jones : Good afternoon, guys, and thanks for taking the question. I guess I’ll slide over to the 002 program. With the Etrasimod data now published, and of course Bill, he was first author. Any thoughts on how that study data impacts your positioning of this year’s year two program. Obviously that study is well underway, but how does that help you and your thinking about positioning the program and getting ready for Phase 3?
